Literature DB >> 21700363

High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection.

V Arora1, S Kachroo, S S Ghantoji, H L Dupont, K W Garey.   

Abstract

Several variables have been proposed to predict the prognosis of patients with Clostridium difficile infection (CDI), but a clinically useful tool to stratify resource utilization has not been determined. Horn's index, a severity score based on underlying clinical illness, reliably predicts patients at high risk of CDI. The purpose of this study was to assess the use of Horn's index to stratify patients with CDI at high risk of poor clinical and economic outcomes. Hospitalized patients diagnosed with CDI were followed prospectively for three months. Horn's index scores were calculated for each patient on the day of the positive toxin test for C. difficile, and used to stratify differences in outcome variables (length of hospital stay, mortality and hospital costs). Eighty-five CDI patients (50% male, 64% Caucasian) were recruited. Discharge mortality was 0% for patients with Horn's index scores of 1 or 2, 5% for those with a score of 3, and 50% for those with a score of 4 (P < 0.001). Three-month mortality was 0%, 5%, 17% and 60% for patients with Horn's index scores of 1, 2, 3 and 4, respectively (P = 0.0004). Median three-month hospital costs were $8,585, $12,670, $29,077 and $68,708 for patients with Horn's index scores of 1, 2, 3 and 4, respectively (P < 0.001). Patients with Horn's index scores of 3 or 4 had a significantly longer hospital stay [mean 33.4 (standard deviation, SD 33.3) days] than patients with scores of 1 or 2 [mean 15.1 (SD 16.2) days, P = 0.001]. This study found Horn's index to be a simple and useful method for identifying CDI patients at high risk of poor clinical and economic outcomes.
Copyright © 2011 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21700363     DOI: 10.1016/j.jhin.2011.04.027

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  11 in total

Review 1.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

Review 2.  The economic impact of Clostridium difficile infection: a systematic review.

Authors:  Natasha Nanwa; Tetyana Kendzerska; Murray Krahn; Jeffrey C Kwong; Nick Daneman; William Witteman; Nicole Mittmann; Suzanne M Cadarette; Laura Rosella; Beate Sander
Journal:  Am J Gastroenterol       Date:  2015-04-07       Impact factor: 10.864

3.  Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole.

Authors:  Vy P Pham; Andrea M Luce; Sara C Ruppelt; Wenjing Wei; Samuel L Aitken; William L Musick; Ryan K Roux; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

4.  External Validation and Comparison of Clostridioides difficile Severity Scoring Systems.

Authors:  D Alexander Perry; Daniel Shirley; Dejan Micic; Pratish C Patel; Rosemary Putler; Anitha Menon; Vincent B Young; Krishna Rao
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

5.  Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.

Authors:  Jiri Drabek; Otakar Nyc; Marcela Krutova; Jan Stovicek; Jana Matejkova; Radan Keil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-12-23       Impact factor: 3.944

6.  A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection.

Authors:  Xi Na; Alan J Martin; Saurabh Sethi; Lorraine Kyne; Kevin W Garey; Sarah W Flores; Mary Hu; Dhara N Shah; Kelsey Shields; Daniel A Leffler; Ciarán P Kelly
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

Review 7.  A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management.

Authors:  Csaba Fehér; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-07-28

8.  Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection.

Authors:  Vicente Boix; Richard N Fedorak; Kathleen M Mullane; Yves Pesant; Uschi Stoutenburgh; Mandy Jin; Adedayo Adedoyin; Laurent Chesnel; Dalya Guris; Kajal B Larson; Yoshihiko Murata
Journal:  Open Forum Infect Dis       Date:  2017-01-19       Impact factor: 3.835

9.  Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire.

Authors:  Kevin W Garey; Samuel L Aitken; Liliane Gschwind; Sumana Goddu; Yang Xie; Catherine Duff; Frédéric Barbut; Dhara N Shah; Herbert L DuPont
Journal:  J Clin Gastroenterol       Date:  2016-09       Impact factor: 3.062

Review 10.  Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.

Authors:  Shanshan Zhang; Sarah Palazuelos-Munoz; Evelyn M Balsells; Harish Nair; Ayman Chit; Moe H Kyaw
Journal:  BMC Infect Dis       Date:  2016-08-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.